Novus Therapeutics, Inc. Share Price Nasdaq
Equities
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 33.33M 2.78B | Capitalization | 74.94M 6.24B |
---|---|---|---|---|---|
Net income 2024 * | -47M -3.91B | Net income 2025 * | -33M -2.75B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.25 x |
P/E ratio 2024 * |
-2.68
x | P/E ratio 2025 * |
-4.84
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.5% |
Latest transcript on Novus Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 01/20/01 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 15/21/15 |
Steven Perrin
PSD | President | 59 | 14/20/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 01/17/01 |
Walter Ogier
BRD | Director/Board Member | 67 | 14/20/14 |
John McBride
BRD | Director/Board Member | 72 | 01/17/01 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |